×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北京... [7]
吉林大学白求恩第一医... [5]
复旦大学上海医学院 [4]
山东大学 [2]
吉林大学白求恩第三医... [2]
西安交通大学 [1]
更多...
内容类型
期刊论文 [17]
会议论文 [10]
发表日期
2019 [9]
2018 [13]
2016 [5]
学科主题
oncology [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共27条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis
期刊论文
CLINICAL RHEUMATOLOGY, 2019, 卷号: 38, 期号: 6
作者:
Dong, Yidian
;
Li, Ping
;
Xu, Tingshuang
;
Bi, Liqi
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2019/12/05
Ankylosing spondylitis
Biological therapy
Drug monitoring
Etanercept
Pharmacokinetics
A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
期刊论文
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 卷号: 57, 期号: 3
作者:
Li, Cuiyun
;
Zhang, Hong
;
Zhu, Xiaoxue
;
Wei, Haijing
;
Chen, Hong
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2019/12/05
biosimilar
phase I
IBI305
bevacizumab
pharmacokinetics
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
期刊论文
DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 卷号: 13
作者:
An, Qing
;
Zheng, Yingxin
;
Zhao, Yirong
;
Liu, Tao
;
Guo, Huaizu
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2019/12/05
infliximab
biosimilar
"biobetter"
CMAB008
immunogenicity
HS016, A PROPOSED ADALIMUMAB BIOSIMILAR, SHOWED EQUIVALENT PHARMACOKINETICS AND SIMILAR SAFETY, IMMUNOGENICITY AND TOLERABILITY TO CHINA-LICENSED ADALIMUMAB IN HEALTHY MALE SUBJECTS, ACCORDING TO A 2.3-MONTHS PHASE I STUDY
会议论文
作者:
Cao, Guoying
;
Yu, Jicheng
;
Wang, Jingjing
;
Yang, Xiaoli
;
Xue, Yu
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2019/12/05
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects
期刊论文
BIODRUGS, 2019, 卷号: 33, 期号: 1
作者:
Zhang, Tan
;
Chen, Guihong
;
Liu, Chang
;
Zu, Li'an
;
Wang, Qi
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2019/12/05
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects
期刊论文
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2019, 卷号: 33, 页码: 93-100
作者:
Zhang Tan[1]
;
Chen Guihong[2]
;
Liu Chang[3]
;
Zu Li'an[4]
;
Wang Qi[5]
收藏
  |  
浏览/下载:38/0
  |  
提交时间:2019/04/22
EFFICACY, PHARMACOKINETICS, SAFETY AND IMMUNOGENICITY OF THE BIOSIMILAR HS016 IN COMPARISON WITH ADALIMUMAB IN CHINESE PATIENTS WITH ANKYLOSING SPONDYLITIS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 3 TRIAL
会议论文
ANNALS OF THE RHEUMATIC DISEASES, 2019-06-01
作者:
Su, Jinmei
;
Li Mengtao
;
Zeng, Xiaofeng
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2020/01/03
EFFICACY, PHARMACOKINETICS, SAFETY AND IMMUNOGENICITY OF THE BIOSIMILAR HS016 IN COMPARISON WITH ADALIMUMAB IN CHINESE PATIENTS WITH ANKYLOSING SPONDYLITIS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 3 TRIAL
期刊论文
2019, 卷号: 78, 页码: 894-894
作者:
Su, Jinmei
;
Li Mengtao
;
Zeng, Xiaofeng
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2020/01/03
BIOSIMILAR BAT1406 VERSUS ADALIMUMAB THERAPY ON ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLINDED, MULTICENTER, CONTROLLED PHASE 3 TRIAL
会议论文
Annual European Congress of Rheumatology (EULAR), JUN 12-15, 2019
作者:
Tu, Liudan
;
Wei, Qiujing
;
Xie, Ya
;
Shi, Guixiu
;
Liu, Huaxiang
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2019/12/31
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study
期刊论文
ARTHRITIS & RHEUMATOLOGY, 2018, 卷号: 70
作者:
Wu, Lijun
;
Xu Huji
;
Li Zhijun
;
Jian, Wu
;
Qian, Xing
收藏
  |  
浏览/下载:26/0
  |  
提交时间:2019/12/05
©版权所有 ©2017 CSpace - Powered by
CSpace